5月22日，港股上市公司荣昌生物（09995.HK）股价出现显著波动，盘中大涨5.01%，引起市场广泛关注。
消息面上，荣昌生物于当日早间宣布了一项配股计划。公司拟以每股42.44港元的价格配售1900万股新H股，较5月21日收盘价折让约9.51%。此次配股预计募集资金净额约7.96亿港元，公司计划将所得资金用于投资核心产品泰它西普（RC18）的核心适应症拓展，如重症肌无力、膜性肾病等，以及其他一般企业用途。
值得注意的是，荣昌生物股价在早盘交易中曾一度跌至44.1港元，跌幅接近6%。然而，随着投资者对公司配股计划的深入理解和认可，股价在盘中出现显著反弹。分析人士认为，尽管配股价格有所折让，但投资者对公司未来发展前景保持信心，特别是对核心产品泰它西普在多个适应症上的拓展潜力抱有期待，这可能是推动股价上涨的主要原因。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.